Senate FDA User Fee Bill’s Mandatory Supplement Listing Provision Unites Industry In Opposition
Senate HELP Committee didn’t add amendments to user fee bill to protect confidential information and prevent FDA over-regulation in an MPL program, trade groups say. MPL proponents join opponents in saying language in S.4348 isn’t the answer.
You may also be interested in...
Senate votes down Illinois Democrat’s proposal to amend stopgap appropriations bill with language calling for establishing mandatory products listing program in FDA. But proposal to give FDA MPL authority likely will return in Congress, says Natural Products Association.
With current user fee package as well all federal spending programs for FY2022 expiring on 30 September, House and Senate committee leaders reach agreement on FDA user fee reauthorization included in a continuing resolution to extend federal spending at current levels through 16 December.
Members led by SC Republican Jeff Duncan and CA Democrat Tony Cárdenas, in letter to House speaker and minority leader, oppose MPL provision in latest version of S.4348 for re-authorizing FDA drug, biologic and medical device user fee programs.